Marshall HS - Search Results

1

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

McLeod C, Dymock M, Flanagan KL, Plebanski M, Marshall HS, Estcourt MJ, Wadia U, Tjiam MC, Blyth CC, Subbarao K, Mordant FL, Nicholson S, Cain N, Brizuela R, Faust SN, Thornton RB, Ellis Z, Mckenzie A, Marsh JA, Snelling TL, Richmond PC. McLeod C, et al. Among authors: marshall hs. J Infect. 2024 Dec;89(6):106346. doi: 10.1016/j.jinf.2024.106346. Epub 2024 Nov 15. J Infect. 2024. PMID: 39550007 Free article. Clinical Trial.

2

A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.

Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet JM, Schuerman L. Marshall H, et al. Vaccine. 2006 Aug 28;24(35-36):6120-8. doi: 10.1016/j.vaccine.2006.05.017. Epub 2006 Jun 2. Vaccine. 2006. PMID: 16822597 Clinical Trial.

3

Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.

Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group. Nolan T, et al. Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064. Pediatrics. 2008. PMID: 18310199 Clinical Trial.

4

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, Hartel G, Lai M, Basser R, Gittleson C, Greenberg M. Nolan T, et al. JAMA. 2010 Jan 6;303(1):37-46. doi: 10.1001/jama.2009.1911. Epub 2009 Dec 21. JAMA. 2010. PMID: 20026597 Clinical Trial.

5

Th2-polarisation of cellular immune memory to neonatal pertussis vaccination.

White OJ, Rowe J, Richmond P, Marshall H, McIntyre P, Wood N, Holt PG. White OJ, et al. Vaccine. 2010 Mar 19;28(14):2648-52. doi: 10.1016/j.vaccine.2010.01.010. Epub 2010 Jan 20. Vaccine. 2010. PMID: 20096390

6

Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.

Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, Aris E, Miller J, Poolman J, Boutriau D. Nolan T, et al. Pediatr Infect Dis J. 2011 Mar;30(3):190-6. doi: 10.1097/INF.0b013e3181fcb2bf. Pediatr Infect Dis J. 2011. PMID: 20948453 Clinical Trial.

7

Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old.

Quinn P, Gold M, Royle J, Buttery J, Richmond P, McIntyre P, Wood N, Lee SS, Marshall H. Quinn P, et al. Vaccine. 2011 Jun 6;29(25):4230-7. doi: 10.1016/j.vaccine.2011.03.088. Epub 2011 Apr 15. Vaccine. 2011. PMID: 21497629 Clinical Trial.

8

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C. McVernon J, et al. Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34. Pediatr Infect Dis J. 2012. PMID: 22094636 Free article. Clinical Trial.

9

Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.

Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL. Marshall HS, et al. Pediatr Infect Dis J. 2012 Oct;31(10):1061-8. doi: 10.1097/INF.0b013e31826327e4. Pediatr Infect Dis J. 2012. PMID: 22718089 Clinical Trial.

10

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.

Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, Jones TR, Arora A. Richmond PC, et al. Among authors: marshall hs. Vaccine. 2012 Sep 21;30(43):6163-74. doi: 10.1016/j.vaccine.2012.07.065. Epub 2012 Aug 5. Vaccine. 2012. PMID: 22871351 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

237 results

Search Page

Filters